Hong Kong stock Concept tracking | Deepseek sparks an AI Medical craze, increasing the valuation of the Medical Sector (including Concept stocks).

Frost & Sullivan predicts that by 2033, the Medical AI market in China will grow from 8.8 billion yuan in 2023 to 315.7 billion yuan, with a compound annual growth rate of 43.1%.

Zhitong FinanceMar 7 09:41

CHUNLI MEDICAL (688236.SH): A total of 0.226% of the company's shares have been repurchased.

On March 4, Gelonghui reported that CHUNLI MEDICAL (688236.SH) announced that as of February 28, 2025, the company has cumulatively repurchased 868,145 shares of its stock through the centralized bidding trading system of the Shanghai Stock Exchange, accounting for 0.226% of the company's total share capital. The highest price for the buyback was 15.96 yuan per share, the lowest was 12.09 yuan per share, and the total amount of funds paid was 12,018,864.19 yuan (excluding transaction fees).

Gelonghui FinanceMar 4 17:16

Hong Kong stocks movement | CHUNLI MEDICAL (01858) fell over 5%, significantly impacted by the centralized procurement policy. The company's net profit decreased by 55% year-on-year last year.

CHUNLI MEDICAL (01858) fell more than 5%. As of the time of this report, it has decreased by 5.13%, priced at 8.7 Hong Kong dollars, with a transaction volume of 2.8645 million Hong Kong dollars.

Zhitong FinanceFeb 28 11:06

Announcement Summary | Several Biomedical stocks announced their Earnings Reports, BEIGENE's revenue increased by 56% year-on-year last year.

① BEIGENE's revenue exceeds 27 billion yuan in 2024, how is the profitability? ② SHK PPT's mid-term profit decreased by nearly 20%, how significant is the impact?

cls.cnFeb 28 08:27

Chunli Healthcare: 2024 Annual Results Report Announcement

SZSIFeb 28 00:00 · Announcements

2024 Annual Results Express Announcement

SZSIFeb 28 00:00 · Announcements

Chunlizhengda Medical Instruments' 2024 Profit Plummets 55%

MT NewswiresFeb 27 19:38

The "Performance Flash Report" indicates that CHUNLI MEDICAL (01858.HK) had a net profit of 0.125 billion yuan for the full year, a decline of 55%.

CHUNLI MEDICAL (01858.HK) announced its performance report. According to the unaudited results for the full year ending December last year, the revenue was 0.806 billion yuan (RMB), a year-on-year decrease of 33.3%. The net profit was 0.125 billion yuan, representing a year-on-year decline of 55%; earnings per share were 0.33 yuan.

AASTOCKSFeb 27 17:54

CHUNLI MEDICAL: PRELIMINARY RESULTS FOR THE YEAR OF 2024

HKEXFeb 27 17:52 · Announcements

Express News | CHUNLI MEDICAL: The net income for 2024 is 0.125 billion yuan, a year-on-year decrease of 55.01%.

BreakingsFeb 27 17:40

The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.

On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China will benefit from the AI revolution, from drug development and diagnostics to hospital management.

wallstreetcnFeb 27 16:39

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 27 09:37

AI hotspots continue to boost! Most Medical stocks in Hong Kong strengthen, with Micro-invasion Siasun Robot&Automation rising over 20%.

How does Sister Wood perceive this hot topic of AI Medical? What positive impacts will the emergence of DeepSeek bring to the medical field?

cls.cnFeb 10 11:58

As of the end of January, CHUNLI MEDICAL (01858) has repurchased a total of 0.8681 million A-shares.

CHUNLI MEDICAL (01858) announced that as of January 31, 2025, the company will conduct transactions through the Shanghai Exchange...

Zhitong FinanceFeb 7 13:23

Chunlizhengda Medical Instruments' 2024 Profit to Slip Up to 61%

MT NewswiresJan 27 18:09

The profit warning indicates that CHUNLI MEDICAL (01858.HK) expects a decline in net profit of 54%-61% last year.

CHUNLI MEDICAL (01858.HK) issues a profit warning, expecting a net profit of between 0.108 billion and 0.128 billion RMB for the fiscal year 2024, a decrease of 54%-61.2% compared to the previous year. This is mainly due to the ongoing deepening of centralized procurement policies.

AASTOCKSJan 26 21:38

2024 Annual Results Forecast Announcement

SZSIJan 25 00:00 · Announcements

CHUNLI MEDICAL: ANNOUNCEMENT ON ESTIMATED RESULTS FOR THE YEAR 2024

HKEXJan 24 20:40 · Announcements

CHUNLI MEDICAL (688236.SH): The net income for the year 2024 is expected to decrease by 53.99% to 61.19%.

On January 24, Gelonghui reported that CHUNLI MEDICAL (688236.SH) announced its performance forecast for 2024. According to preliminary calculations by the finance department, it is expected that the annual net income attributable to the owners of the parent company will be between 107.824 million yuan and 127.824 million yuan, which represents a decrease of 150 million yuan to 170 million yuan compared to the same period last year, a year-on-year decrease of 53.99% to 61.19%. The net income attributable to the owners of the parent company, excluding non-recurring gains and losses, is expected to be between 79.1283 million yuan and 99.1283 million yuan, compared to the same period last year.

Gelonghui FinanceJan 24 19:20

Express News | CHUNLI MEDICAL: The net income for the year 2024 is expected to decrease by 53.99%-61.19% year-on-year.

BreakingsJan 24 18:25